.
MergerLinks Header Logo

Announced

Completed

Grifols completed the acquisition of an 89.88% stake in Biotest for $1.2bn.

Financials

Edit Data
Transaction Value£926m
Consideration TypeCash, Loan Notes
Capital Owned-
Capital Bid For90%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Germany

Majority

Biotechnology

Private

Acquisition

Single Bidder

Friendly

plasma protein

Cross Border

Completed

Synopsis

Edit

Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, completed the acquisition of an 89.88% stake in Biotest, a biotechnology company, for $1.2bn. “This unique opportunity will allow Grifols and Biotest to mark a new milestone while shaping the plasma industry. It will enlarge our existing portfolio of plasma-derived therapies and fast-track the development of new products, with a concerted focus on delivering value to patients, shareholders and other key stakeholders. We look forward to partnering with the Biotest team," Raimon Grífols Roura, Grifols co-CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US